Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Therasse · SciRah

Researcher profile · Semantic Scholar

P. Therasse

Share profile

P. Therasse — researcher profile on SciRah

h-index: 51
Works: 146
Citations: 67K

Most-cited papers

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz +12 more
2009European Journal of Cancer27K citations
Semantic Scholar
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
L. Seymour, J. Bogaerts, A. Perrone, R. Ford +14 more
2017The Lancet Oncology2,125 citations Open access
Semantic Scholar
RECIST 1.1 – Update and Clarification: From the RECIST Committee
Lawrence H. Schwartz, S. Litière, E. D. de Vries, R. Ford +15 more
2016European Journal of Cancer1,840 citations Open access
Semantic Scholar
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
M. Buyse, S. Loi, L. V. van'T Veer, G. Viale +16 more
2006Journal of the National Cancer Institute1,248 citations Open access
Semantic Scholar
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
P. Goss, J. Ingle, S. Martino, N. Robert +14 more
2004New England Journal of Medicine1,012 citations
Semantic Scholar
RECIST revisited: a review of validation studies on tumour assessment.
P. Therasse, E. Eisenhauer, J. Verweij
2006European Journal of Cancer447 citations
Semantic Scholar
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
J. Vansteenkiste, B. Cho, T. Vanakesa, T. De Pas +26 more
2016The Lancet Oncology427 citations Open access
Semantic Scholar
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz, L. Seymour, S. Litière, R. Ford +15 more
2016European Journal of Cancer352 citations Open access
Semantic Scholar
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
T. Burzykowski, M. Buyse, M. Piccart-Gebhart, G. Sledge +12 more
2008Journal of Clinical Oncology344 citations Open access
Semantic Scholar
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
R. Paridaens, L. Dirix, L. Beex, M. Nooij +5 more
2008Journal of Clinical Oncology305 citations Open access
Semantic Scholar
Evaluation of lymph nodes with RECIST 1.1.
L. Schwartz, J. Bogaerts, R. Ford, L. Shankar +3 more
2009European Journal of Cancer282 citations
Semantic Scholar
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
J. Bogaerts, F. Cardoso, M. Buyse, S. Braga +10 more
2006Nature Clinical Practice Oncology259 citations
Semantic Scholar
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
P. Therasse, L. Mauriac, M. Wełnicka-Jaśkiewicz, P. Bruning +6 more
2003Journal of Clinical Oncology230 citations
Semantic Scholar
Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
F. Lecouvet, Daphné Geukens, A. Stainier, F. Jamar +5 more
2007Journal of Clinical Oncology227 citations Open access
Semantic Scholar
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart, T. Burzykowski, M. Buyse, G. Sledge +12 more
2008Journal of Clinical Oncology214 citations Open access
Semantic Scholar
Individual patient data analysis to assess modifications to the RECIST criteria.
J. Bogaerts, R. Ford, D. Sargent, L. Schwartz +5 more
2009European Journal of Cancer201 citations
Semantic Scholar
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
C. Praga, J. Bergh, J. Bliss, J. Bonneterre +15 more
2005Journal of Clinical Oncology189 citations Open access
Semantic Scholar
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
B. Dréno, John F. Thompson, B. M. Smithers, M. Santinami +34 more
2018The Lancet Oncology159 citations Open access
Semantic Scholar
Health related quality of life outcomes in cancer clinical trials.
A. Bottomley, H. Flechtner, F. Efficace, V. Vanvoorden +5 more
2005European Journal of Cancer159 citations
Semantic Scholar
Recommendations for the assessment of progression in randomised cancer treatment trials.
J. Dancey, Lori E. Dodd, R. Ford, R. M. Kaplan +5 more
2009European Journal of Cancer123 citations
Semantic Scholar
Lessons learned from independent central review.
R. Ford, L. Schwartz, J. Dancey, Lori E. Dodd +7 more
2009European Journal of Cancer116 citations
Semantic Scholar
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
F. Efficace, P. Therasse, M. Piccart, C. Coens +9 more
2004Journal of Clinical Oncology116 citations
Semantic Scholar
Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy.
I. Fentiman, M. Christiaens, R. Paridaens, A. V. van Geel +7 more
2003European Journal of Cancer113 citations
Semantic Scholar
TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network.
M. Morente, R. Mager, S. Alonso, F. Pezzella +24 more
2006European Journal of Cancer94 citations
Semantic Scholar
Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases
B. Tombal, A. Rezazadeh, P. Therasse, P. V. van Cangh +2 more
2005The Prostate94 citations
Semantic Scholar
First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
R. Paridaens, P. Therasse, L. Dirix, L. Beex +6 more
200484 citations
Semantic Scholar
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H. Bonnefoi, S. Diebold‐Berger, P. Therasse, A. Hamilton +8 more
2003Annals of Oncology77 citations Open access
Semantic Scholar
32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz +11 more
200876 citations
Semantic Scholar
TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe.
E. van Veen, P. Riegman, W. Dinjens, K. Lam +23 more
2006European Journal of Cancer71 citations
Semantic Scholar
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
S. Litière, Gaëlle Isaac, E. D. de Vries, J. Bogaerts +13 more
2019Journal of Clinical Oncology67 citations Open access
Semantic Scholar
Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste, M. Zielinski, I. Dahabreh, A. Linder +5 more
200863 citations
Semantic Scholar
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
P. Therasse, A. Le Cesne, M. Van Glabbeke, J. Verweij +1 more
2005European Journal of Cancer61 citations
Semantic Scholar
Immune-Related Response Criteria
P. Therasse
2020Definitions59 citations Open access
Semantic Scholar
Improving cancer outcomes through international collaboration in academic cancer treatment trials.
E. Trimble, J. Abrams, R. Meyer, F. Calvo +16 more
2009Journal of Clinical Oncology58 citations Open access
Semantic Scholar
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).
L. Biganzoli, A. Goldhirsch, C. Straehle, M. Castiglione-Gertsch +4 more
2004Annals of Oncology57 citations Open access
Semantic Scholar
1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).
J. Vansteenkiste, B. Cho, T. Vanakesa, T. De Pas +16 more
2014Annals of Oncology49 citations Open access
Semantic Scholar
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
A. Bottomley, P. Therasse, M. Piccart, F. Efficace +10 more
2005The Lancet Oncology47 citations
Semantic Scholar
First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group.
R. Paridaens, P. Therasse, L. Dirix, L. Beex +6 more
2004Journal of Clinical Oncology46 citations
Semantic Scholar
TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview.
P. Riegman, W. Dinjens, M. Oomen, A. Spatz +25 more
2006European Journal of Cancer45 citations
Semantic Scholar
Human tissue research: EORTC recommendations on its practical consequences.
I. Teodorović, P. Therasse, Alain Spatz, M. Isabelle +1 more
2003European Journal of Cancer39 citations
Semantic Scholar
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
L. Biganzoli, R. Coleman, A. Minisini, A. Hamilton +5 more
2007Critical reviews in oncology/hematology38 citations
Semantic Scholar
Cancer clinical trial outcomes: any progress in tumour-size assessment?
J. Verweij, P. Therasse, E. Eisenhauer
2009European Journal of Cancer35 citations
Semantic Scholar
TuBaFrost 6: virtual microscopy in virtual tumour banking.
I. Teodorović, M. Isabelle, A. Carbone, A. Passioukov +25 more
2006European Journal of Cancer29 citations
Semantic Scholar
Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms
F. Lehmann, D. Lacombe, P. Therasse, A. Eggermont
2003Journal of Translational Medicine28 citations Open access
Semantic Scholar
Pattern of care in locally advanced breast cancer: focus on local therapy.
M. Sinacki, A. Badzio, M. Wełnicka-Jaśkiewicz, J. Bogaerts +5 more
2011Breast27 citations Open access
Semantic Scholar
Update in methodology and conduct of cancer clinical trials.
P. Therasse, E. Eisenhauer, M. Buyse
2006European Journal of Cancer26 citations
Semantic Scholar
TuBaFrost 5: multifunctional central database application for a European tumor bank.
M. Isabelle, I. Teodorović, M. Morente, D. Jaminé +25 more
2006European Journal of Cancer26 citations
Semantic Scholar
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
P. Saiag, R. Gutzmer, P. Ascierto, M. Maio +16 more
2016Annals of Oncology23 citations Open access
Semantic Scholar
TuBaFrost 4: access rules and incentives for a European tumour bank.
J. López-Guerrero, P. Riegman, J. Oosterhuis, K. Lam +24 more
2006European Journal of Cancer22 citations Open access
Semantic Scholar
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
M. Smoragiewicz, J. Bogaerts, E. Calvo, A. Marabelle +20 more
2018Annals of Oncology20 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Bogaerts×14
Invite
J. Bogaerts — researcher profile on SciRah
M. Piccart×14
Invite
M. Piccart — researcher profile on SciRah
R. Ford×10
Invite
R. Ford — researcher profile on SciRah
L. Shankar×10
Invite
L. Shankar — researcher profile on SciRah

×9

Invite

E. Eisenhauer — researcher profile on SciRah

Invite

J. Dancey — researcher profile on SciRah

M. J. van de Vijver×7

Invite

M. J. van de Vijver — researcher profile on SciRah

I. Teodorović×7

Invite

I. Teodorović — researcher profile on SciRah

Invite

L. Schwartz — researcher profile on SciRah

Invite

J. Verweij — researcher profile on SciRah

R. Paridaens×6

Invite

R. Paridaens — researcher profile on SciRah

Invite

T. Čufer — researcher profile on SciRah